Pulmonary Benign Metastasizing Leiomyoma in Patients Aged 45 Years and Younger: Clinical Features and Novelty in Treatment

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 May 15

PMID 37189093

Authors

Hao Su

Rong Fan

Hua Yang

Yan You

Lan Zhu

Fengzhi Feng

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary benign metastasizing leiomyoma (PBML) is the most common extrauterine spread of uterine leiomyoma, and its biological behavior is traditionally thought to be hormone dependent. Studies on older PBML patients have been previously reported, but limited literature has been published regarding the clinical features and treatment of PBML in young women.

Methods: A total of 65 cases of PBML in women aged 45 years and younger were reviewed, including 56 cases selected from PubMed and 9 cases from our hospital. The clinical characteristics and management of these patients were analyzed.

Results: The median age of all the patients at diagnosis was 39.0 years. PBML most commonly presented as bilateral solid lesions (60.9%), with other rare imaging manifestations. The median interval time from a pertinent gynecologic procedure to diagnosis was 6.0 years. A total of 16.7% of patients received careful observation, and all achieved stable status in a median follow-up time of 18.0 months. A total of 71.4% of patients were administered anti-estrogen therapies, including surgical castration (33.3%), gonadotropin-releasing hormone analog (23.8%) and anti-estrogen drugs (14.3%). Eight of 42 patients underwent surgical resection of metastatic lesions. Patients who underwent curative surgery for the removal of pulmonary lesions combined with adjuvant anti-estrogen therapies had favorable outcomes compared with those who only underwent surgical resection. The disease control rates of surgical castration, gonadotropin-releasing hormone analog, and anti-estrogen drugs were 85.7%, 90.0%, and 50.0%, respectively. For two patients, sirolimus (rapamycin) achieved successful relief of symptoms and control of pulmonary lesions without lowering hormone levels and causing estrogen deficiency symptoms.

Conclusions: In the absence of standard treatment guidelines for PBML, maintaining a low-estrogen environment using different kinds of antiestrogen therapies has been the mainstream strategy and has satisfying curative effects. A wait-and-see strategy might be an option, but therapeutic approaches must be contemplated when complications or symptoms progress. For PBML in young women, the negative effect on ovarian function of anti-estrogen treatment, especially surgical castration, should be considered. Sirolimus might be a new treatment option for young PBML patients, especially for those who want to preserve ovarian function.

Citing Articles

Pulmonary benign metastasizing leiomyoma presenting as acute hypoxemic respiratory failure: a case report.

Lin Y, Chu J, Qiao W, Yu C, Gao C BMC Pulm Med. 2024; 24(1):376.

PMID: 39090648 PMC: 11295507. DOI: 10.1186/s12890-024-03189-1.

Rare manifestation of pulmonary benign metastasizing leiomyoma: Respiratory failure.

Araujo N, Cardoso I, Jatoba T, Mencato Sabey L, Teixeira A, Tojal A Respir Med Case Rep. 2024; 50:102053.

PMID: 38881776 PMC: 11176773. DOI: 10.1016/j.rmcr.2024.102053.

References

Ottlakan A, Borda B, Lazar G, Tiszlavicz L, Furak J . Treatment decision based on the biological behavior of pulmonary benign metastasizing leiomyoma. J Thorac Dis. 2016; 8(8):E672-6. PMC: 4999677. DOI: 10.21037/jtd.2016.06.61. View

Zhang X, Li L, Xu J, Wang N, Liu W, Lin X . Rapamycin preserves the follicle pool reserve and prolongs the ovarian lifespan of female rats via modulating mTOR activation and sirtuin expression. Gene. 2013; 523(1):82-7. DOI: 10.1016/j.gene.2013.03.039. View

Rivera J, Christopoulos S, Small D, Trifiro M . Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab. 2004; 89(7):3183-8. DOI: 10.1210/jc.2003-032021. View

Zhang G, Feng F, Wang W, Zhu L . Rapamycin (sirolimus) in treatment of recurrent intravenous leiomyomatosis: a case report. BJOG. 2020; 127(6):768-771. DOI: 10.1111/1471-0528.16156. View

Hu S, Wu X, Xu W, Tian X, Yang Y, Wang S . Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis. Orphanet J Rare Dis. 2019; 14(1):206. PMC: 6702727. DOI: 10.1186/s13023-019-1178-2. View

Chen A, Setser A, Anadkat M, Cotliar J, Olsen E, Garden B . Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012; 67(5):1025-39. DOI: 10.1016/j.jaad.2012.02.010. View

Fan R, Feng F, Yang H, Xu K, Li S, You Y . Pulmonary benign metastasizing leiomyomas: a case series of 23 patients at a single facility. BMC Pulm Med. 2020; 20(1):292. PMC: 7653756. DOI: 10.1186/s12890-020-01330-4. View

Pacheco-Rodriguez G, Taveira-DaSilva A, Moss J . Benign Metastasizing Leiomyoma. Clin Chest Med. 2016; 37(3):589-95. DOI: 10.1016/j.ccm.2016.04.019. View

Chhabra S, Sangani P, Saig R, Stany M . Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis. Gynecol Oncol Rep. 2022; 39:100903. PMC: 9068955. DOI: 10.1016/j.gore.2021.100903. View

10.

Park J, Chae B, Kim M . The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma. Int J Med Sci. 2022; 19(12):1779-1786. PMC: 9608041. DOI: 10.7150/ijms.75203. View

11.

Miller J, Shoni M, Siegert C, Lebenthal A, Godleski J, McNamee C . Benign Metastasizing Leiomyomas to the Lungs: An Institutional Case Series and a Review of the Recent Literature. Ann Thorac Surg. 2015; 101(1):253-8. DOI: 10.1016/j.athoracsur.2015.05.107. View

12.

Jiang J, He M, Hu X, Ni C, Yang L . Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma. Clin Transl Oncol. 2018; 20(8):1080-1086. DOI: 10.1007/s12094-018-1847-y. View

13.

Zhou C, Liu C, Liu W, Chen W, Yin Y, Li C . SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020; 10(10):4627-4643. PMC: 7150495. DOI: 10.7150/thno.42869. View

14.

Sarrel P, Sullivan S, Nelson L . Hormone replacement therapy in young women with surgical primary ovarian insufficiency. Fertil Steril. 2016; 106(7):1580-1587. PMC: 5248494. DOI: 10.1016/j.fertnstert.2016.09.018. View

15.

Barnas E, Ksiazek M, Ras R, Skret A, Skret-Magierlo J, Dmoch-Gajzlerska E . Benign metastasizing leiomyoma: A review of current literature in respect to the time and type of previous gynecological surgery. PLoS One. 2017; 12(4):e0175875. PMC: 5398563. DOI: 10.1371/journal.pone.0175875. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Commandeur A, Styer A, Teixeira J . Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 2015; 21(5):593-615. PMC: 4533663. DOI: 10.1093/humupd/dmv030. View

18.

McWilliams M, Chennathukuzhi V . Recent Advances in Uterine Fibroid Etiology. Semin Reprod Med. 2017; 35(2):181-189. PMC: 5490981. DOI: 10.1055/s-0037-1599090. View

19.

Luo L, Xu J, Fu Y . Rapamycin prolongs female reproductive lifespan. Cell Cycle. 2013; 12(21):3353-4. PMC: 3895422. DOI: 10.4161/cc.26578. View

20.

Agackiran Y, Findik G, Ustun L, Aydogdu K, Kaya S . Pulmonary Benign Metastasizing Leiomyoma: An Extremely Rare Case. Turk Patoloji Derg. 2014; . DOI: 10.5146/tjpath.2013.01217. View